More than 200 years ago, the first vaccine was developed for smallpox, and now, the disease has been eradicated worldwide. And in the United States, the transmission of poliovirus, measles and rubella have been eliminated. These are examples of tremendous scientific progress, and through our growing understanding of how these and other diseases work at the molecular level, many new therapeutic and preventative vaccines have been developed.
A new PhRMA report, “Medicines in Development for Vaccines,” offers insight into the more than 250 vaccines currently in development, designed to prevent and treat illness. More than two-thirds of the vaccines in the last 25 years have been developed in the United States – underscoring the commitment of America’s biopharmaceutical research companies despite a particularly challenging research and development process.
Vaccines in development today will help prevent or treat a number of conditions, including:
- 124 for infectious diseases; and
- 105 for cancer.
Thanks to the perseverance of researchers and scientists, patients are reaping the benefits of innovative medicines to protect against many more life-threatening diseases in years to come.
View the full report here.
Hannah Mooney Hannah is a Director of Public Affairs at PhRMA, managing the creative development and design of PhRMA-branded advocacy campaigns through paid, earned, and digital campaigns. She also manages the day-to-day operations of the Partnership for Prescription Assistance. In a former life, she worked in grassroots advocacy and in the U.S. Senate, but today, she enjoys the challenge of creative development and storytelling. When she’s not at her desk, Hannah is part of the D.C. fitness community and enjoys being active and outdoors, exploring all the city has to offer.